Shares of ResMed Inc. (NYSE:RMD) have been given a consensus rating of “Hold” by the thirteen research firms that are covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $70.57.
RMD has been the subject of several recent analyst reports. BMO Capital Markets upped their target price on shares of ResMed from $70.00 to $74.00 and gave the stock a “market perform” rating in a report on Friday, October 27th. Needham & Company LLC reaffirmed a “sell” rating on shares of ResMed in a report on Friday, October 27th. Zacks Investment Research downgraded shares of ResMed from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. JPMorgan Chase & Co. upped their target price on shares of ResMed from $72.00 to $73.00 and gave the stock an “overweight” rating in a report on Monday, October 30th. Finally, Barclays increased their price objective on shares of ResMed from $68.00 to $70.00 and gave the company an “underweight” rating in a report on Friday, October 27th.
In related news, insider David Pendarvis sold 6,364 shares of the stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $82.20, for a total value of $523,120.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $84.50, for a total transaction of $105,625.00. Following the completion of the transaction, the chief financial officer now directly owns 71,772 shares of the company’s stock, valued at approximately $6,064,734. The disclosure for this sale can be found here. Insiders have sold a total of 158,929 shares of company stock valued at $13,181,009 in the last three months. Insiders own 1.77% of the company’s stock.
Shares of ResMed (NYSE RMD) traded up $0.06 during trading on Monday, reaching $88.79. 585,449 shares of the company traded hands, compared to its average volume of 490,321. The company has a market cap of $12,467.68, a P/E ratio of 35.95, a P/E/G ratio of 2.22 and a beta of 0.79. The company has a debt-to-equity ratio of 0.50, a current ratio of 4.72 and a quick ratio of 3.86. ResMed has a one year low of $62.64 and a one year high of $89.21.
ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.66 earnings per share for the quarter, hitting the consensus estimate of $0.66. The company had revenue of $523.66 million during the quarter, compared to the consensus estimate of $506.08 million. ResMed had a net margin of 16.58% and a return on equity of 21.53%. ResMed’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. analysts anticipate that ResMed will post 3.04 earnings per share for the current fiscal year.
WARNING: This news story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://stocknewstimes.com/2018/01/18/resmed-inc-rmd-receives-65-83-consensus-target-price-from-brokerages.html.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.